Header Logo

RONALD S WALTERS

TitleProfessor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Johnson T, Bandini LAM, Martin K, Jones L, Carlson J, Walters RS, Carlson RW. The State of Cancer Care in America: Impact of State Policy on Access to High-Quality Cancer Care. J Natl Compr Canc Netw. 2020 04; 18(4):400-404. PMID: 32259786.
      Citations:    Fields:    Translation:Humans
    2. Yam C, Murthy RK, Rauch GM, Murray JL, Walters RS, Valero V, Brewster AM, Bast RC, Booser DJ, Giordano SH, Esteva FJ, Yang W, Hortobagyi GN, Moulder SL, Arun B. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-?. Invest New Drugs. 2018 12; 36(6):1103-1109. PMID: 30311036.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    3. Thaker NG, Agarwal A, Palmer M, Hontiveros R, Hahn SM, Minsky BD, Walters R, Bingham J, Feeley TW, Buchholz TA, Frank SJ. Variations in Proton Therapy Coverage in the State of Texas: Defining Medical Necessity for a Safe and Effective Treatment. Int J Part Ther. 2016 Mar; 2(4):499-508. PMID: 31772962; PMCID: PMC6871639.
      Citations: 2     
    4. Fayanju OM, Mayo TL, Spinks TE, Lee S, Barcenas CH, Smith BD, Giordano SH, Hwang RF, Ehlers RA, Selber JC, Walters R, Tripathy D, Hunt KK, Buchholz TA, Feeley TW, Kuerer HM. Value-Based Breast Cancer Care: A Multidisciplinary Approach for Defining Patient-Centered Outcomes. Ann Surg Oncol. 2016 08; 23(8):2385-90. PMID: 26979306.
      Citations: 11     Fields:    Translation:Humans
    5. Gonzalez CE, Johnson TN, Evans S, Kidin LM, George S, Haq S, DeJesus AY, Walters R, Rolston K. Assessing Compliance With Established Pneumonia Core Measures at a Comprehensive Cancer Center. J Healthc Qual. 2015 Jul-Aug; 37(4):232-44. PMID: 24629128; PMCID: PMC4165849.
      Citations:    Fields:    Translation:Humans
    6. Middleton LP, Feeley TW, Albright HW, Walters R, Hamilton SH. Second-opinion pathologic review is a patient safety mechanism that helps reduce error and decrease waste. J Oncol Pract. 2014 Jul; 10(4):275-80. PMID: 24695900.
      Citations: 7     Fields:    Translation:Humans
    7. Abdayem P, Ghosn M, Valero V, Walters R, Arun B, Murray JL, Theriault R, Frye D, Ibrahim NK. Phase I and II Study of Gemcitabine and Vinorelbine in Heavily Pretreated Patients with Metastatic Breast Cancer and Review of the Literature. J Cancer. 2014; 5(5):351-9. PMID: 24723978; PMCID: PMC3982182.
      Citations: 1     
    8. Walters RS. Opportunities for improvement: experience at one institution. J Natl Compr Canc Netw. 2014 Feb; 12 Suppl 1:S36-9. PMID: 24614051.
      Citations:    Fields:    Translation:Humans
    9. Walters RS, Albright HW, Weber RS, Feeley TW, Hanna EY, Cantor SB, Lewis CM, Burke TW. Developing a system to track meaningful outcome measures in head and neck cancer treatment. Head Neck. 2014 Feb; 36(2):226-30. PMID: 23729280.
      Citations: 4     Fields:    Translation:Humans
    10. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5. PMID: 22331946.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    11. Spinks T, Albright HW, Feeley TW, Walters R, Burke TW, Aloia T, Bruera E, Buzdar A, Foxhall L, Hui D, Summers B, Rodriguez A, Dubois R, Shine KI. Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer. 2012 May 15; 118(10):2571-82. PMID: 22045610; PMCID: PMC3272132.
      Citations: 23     Fields:    Translation:Humans
    12. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34. PMID: 22042783; PMCID: PMC3233286.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    13. Tortorella FR, Ewer MS, Douglas-Ntagha PB, Harper G, Walters R, Ecung WB. Developing a transfer center in a tertiary cancer center: streamlining access and communication to accommodate increasing demand for service. J Healthc Manag. 2011 May-Jun; 56(3):199-210; discussion 210-1. PMID: 21714374.
      Citations:    Fields:    Translation:Humans
    14. Spinks TE, Walters R, Feeley TW, Albright HW, Jordan VS, Bingham J, Burke TW. Improving cancer care through public reporting of meaningful quality measures. Health Aff (Millwood). 2011 Apr; 30(4):664-72. PMID: 21471487.
      Citations: 13     Fields:    
    15. Albright HW, Moreno M, Feeley TW, Walters R, Samuels M, Pereira A, Burke TW. The implications of the 2010 Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act on cancer care delivery. Cancer. 2011 Apr 15; 117(8):1564-74. PMID: 21472704.
      Citations: 22     Fields:    Translation:Humans
    16. Feeley TW, Fly HS, Albright H, Walters R, Burke TW. A method for defining value in healthcare using cancer care as a model. J Healthc Manag. 2010 Nov-Dec; 55(6):399-411; discussion 411-2. PMID: 21166323.
      Citations: 11     Fields:    Translation:Humans
    17. Taylor SH, Walters R. Potential impact of tumor registry rule changes for recording inflammatory breast cancer. Cancer. 2010 Jun 01; 116(11 Suppl):2745-7. PMID: 20503404.
      Citations: 5     Fields:    Translation:Humans
    18. Chun J, Grim CJ, Hasan NA, Lee JH, Choi SY, Haley BJ, Taviani E, Jeon YS, Kim DW, Lee JH, Brettin TS, Bruce DC, Challacombe JF, Detter JC, Han CS, Munk AC, Chertkov O, Meincke L, Saunders E, Walters RA, Huq A, Nair GB, Colwell RR. Comparative genomics reveals mechanism for short-term and long-term clonal transitions in pandemic Vibrio cholerae. Proc Natl Acad Sci U S A. 2009 Sep 08; 106(36):15442-7. PMID: 19720995; PMCID: PMC2741270.
      Citations: 192     Fields:    Translation:Cells
    19. Gonzalez-Angulo AM, Walters R, Broglio K, Frye DK, Strom EA, Theriault RL, Booser DJ, Valero V, Buzdar AU, Hortobagyi GN. Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. Clin Breast Cancer. 2008 Dec; 8(6):516-21. PMID: 19073507.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    20. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN, Valero V. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008 Apr 01; 112(7):1455-61. PMID: 18300256.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    21. Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, Langbaum TS, Leedy RD, Muller RJ, Newcomer LN, O'Brien S, Reinke D, Rubino M, Saltz L, Walters RS. NCCN Task Force Report: Oral chemotherapy. J Natl Compr Canc Netw. 2008 Mar; 6 Suppl 3:S1-14. PMID: 18377852.
      Citations: 106     Fields:    Translation:Humans
    22. Walters R, Jones LC. Telethinking. Telemed J E Health. 2007 Jun; 13(3):251-5. PMID: 17603827.
      Citations:    Fields:    Translation:Humans
    23. Beinart GA, Gonzalez-Angulo AM, Broglio K, Frye D, Walters R, Holmes FA, Gunale S, Booser D, Rosenthal J, Dhingra K, Young JA, Hortobagyi GN. Phase II trial of 10-EDAM in the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2007 Jun; 60(1):61-7. PMID: 17009032.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    24. Gonzalez-Angulo AM, Walters RS, Carpenter RJ, Ross MI, Perkins GH, Gwyn K, Theriault RL. Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. Clin Breast Cancer. 2004 Oct; 5(4):317-9. PMID: 15507181.
      Citations: 10     Fields:    Translation:Humans
    25. Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004 Jun 15; 22(12):2294-302. PMID: 15197190.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    26. Rivera E, Valero V, Arun B, Royce M, Adinin R, Hoelzer K, Walters R, Wade JL, Pusztai L, Hortobagyi GN. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol. 2003 Sep 01; 21(17):3249-54. PMID: 12947059.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    27. Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 01; 97(11):2716-23. PMID: 12767083.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    28. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res. 2002 May; 8(5):1073-9. PMID: 12006521.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    29. Rivera E, Holmes FA, Buzdar AU, Asmar L, Kau SW, Fraschini G, Walters R, Theriault RL, Hortobagyi GN. Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease. Breast J. 2002 Jan-Feb; 8(1):2-9. PMID: 11856154.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    30. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66. PMID: 11458813.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    31. Rivera E, Holmes FA, Frye D, Valero V, Theriault RL, Booser D, Walters R, Buzdar AU, Dhingra K, Fraschini G, Hortobagyi GN. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201. PMID: 11147589.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    32. Ibrahim NK, Valero V, Theriault RL, Willey J, Walters RS, Buzdar AU, Booser DJ, Hortobagyi GN. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21. PMID: 10776969.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    33. Booser DJ, Walters RS, Holmes FA, Hortobagyi GN. Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatin for relapsed metastatic breast cancer: a phase II study. Am J Clin Oncol. 2000 Feb; 23(1):40-1. PMID: 10683074.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    34. Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Willey J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34. PMID: 10334527.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    35. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Gibbs H, Fraschini G, Buzdar AU, Willey J, Frye D, Asmar L, Hortobagyi GN. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11. PMID: 10370782.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    36. Pusztai L, Walters RS, Valero V, Theriault RL, Hortobagyi GN. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol. 1998 Oct; 21(5):442-6. PMID: 9781596.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    37. Walters RS, Holmes FA, Valero V, Esparza-Guerra L, Hortobagyi GN. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am J Clin Oncol. 1998 Aug; 21(4):413-5. PMID: 9708645.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    38. Anderson CM, Walters RS, Hortobagyi GN. Mediastinitis related to probable central vinblastine extravasation in a woman undergoing adjuvant chemotherapy for early breast cancer. Am J Clin Oncol. 1996 Dec; 19(6):566-8. PMID: 8931672.
      Citations: 3     Fields:    Translation:Humans
    39. Holmes FA, Madden T, Newman RA, Valero V, Theriault RL, Fraschini G, Walters RS, Booser DJ, Buzdar AU, Willey J, Hortobagyi GN. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21. PMID: 8874332.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    40. Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996 Apr 22; 156(8):882-8. PMID: 8774207.
      Citations: 11     Fields:    Translation:Humans
    41. Theriault RL, Walters RS, Holmes FA, Esparza-Guerra L, Kowal C, Hortobagyi GN. A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N') platinum in patients with refractory advanced breast cancer. Cancer Chemother Pharmacol. 1996; 38(3):289-91. PMID: 8646805.
      Citations:    Fields:    Translation:HumansCellsCTClinical Trials
    42. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec; 13(12):2886-94. PMID: 8523051.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    43. Walters RS, Theriault RL, Booser DJ, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon (rIFN alpha) and continuous-infusion 5-fluorouracil in metastatic breast cancer. J Immunother Emphasis Tumor Immunol. 1995 Oct; 18(3):185-7. PMID: 8770774.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    44. Dhingra K, Frye D, Newman RA, Walters R, Theriault R, Fraschini G, Smith T, Buzdar A, Hortobagyi GN. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer. Clin Cancer Res. 1995 Jul; 1(7):691-7. PMID: 9816034.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    45. Walters RS, Theriault RL, Holmes FA, Esparza L, Hortobagyi GN. Phase II study of recombinant alpha-interferon and recombinant interleukin-2 metastatic breast cancer. J Immunother Emphasis Tumor Immunol. 1994 Nov; 16(4):303-5. PMID: 7881639.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    46. Buzdar AU, Kau S, Hortobagyi GN, Theriault RL, Booser D, Holmes FA, Walters R, Krakoff IH. Phase I trial of droloxifene in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1994; 33(4):313-6. PMID: 8281625.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    47. Holmes FA, Valero V, Walters RS, Theriault RL, Booser DJ, Fraschini G, Buzdar AU, Frye D, Gibbs HR, Hortobagyi GN. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9. PMID: 7912522.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    48. Benvenuto JA, Newman RA, Bignami GS, Raybould TJ, Raber MN, Esparza L, Walters RS. Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer. Invest New Drugs. 1992 Jul; 10(2):113-7. PMID: 1500265.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    49. Walters RS, Theriault RL, Holmes FA, Hortobagyi GN, Esparza L. Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer. Invest New Drugs. 1992 Apr; 10(1):43-4. PMID: 1376723.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    50. Walters RS, Frye D, Buzdar AU, Holmes FA, Hortobagyi GN. A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. Cancer. 1992 Jan 15; 69(2):476-81. PMID: 1728377.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    51. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991 Dec 18; 83(24):1797-805. PMID: 1683908.
      Citations: 137     Fields:    Translation:HumansCTClinical Trials
    52. Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RS, Hortobagyi GN. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol. 1991 Jul; 9(7):1268-74. PMID: 1828499.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    53. Walters R, Kantarjian HM, Keating MJ, Estey EH, Trujillo J, Cork A, McCredie KB, Freireich EJ. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med. 1990 Nov; 89(5):579-87. PMID: 2239977.
      Citations: 5     Fields:    Translation:HumansCells
    54. Hortobagyi GN, Theriault RL, Frye D, Walters RS, Fraschini G, Tashima CK, Ro JS, Salewski E, Buzdar AU. Pirarubicin in combination chemotherapy for metastatic breast cancer. Am J Clin Oncol. 1990; 13 Suppl 1:S54-6. PMID: 2291460.
      Citations: 2     Fields:    Translation:Humans
    55. Kantarjian HM, Walters RL, Keating MJ, Estey EH, O'Brien S, Schachner J, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer. 1990 Jan 01; 65(1):5-8. PMID: 2293869.
      Citations: 3     Fields:    Translation:Humans
    56. Childs CC, Hirsch-Ginsberg C, Walters RS, Andersson BS, Reuben J, Trujillo JM, Cork A, Stass SA, Freireich EJ, Zipf TF. Myeloid surface antigen-positive acute lymphoblastic leukemia (My+ ALL): immunophenotypic, ultrastructural, cytogenetic, and molecular characteristics. Leukemia. 1989 Nov; 3(11):777-83. PMID: 2811478.
      Citations: 10     Fields:    Translation:Humans
    57. Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989 Aug; 7(8):1071-80. PMID: 2666590.
      Citations: 19     Fields:    Translation:Humans
    58. Kantarjian HM, Walters RS, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer. 1989 Jul 01; 64(1):16-22. PMID: 2659160.
      Citations: 4     Fields:    Translation:Humans
    59. Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer. 1989 Mar 01; 63(5):813-7. PMID: 2914287.
      Citations: 19     Fields:    Translation:Humans
    60. Hittelman WN, Agbor P, Petkovic I, Andersson B, Kantarjian H, Walters R, Koller C, Beran M. Detection of leukemic clone maturation in vivo by premature chromosome condensation. Blood. 1988 Dec; 72(6):1950-60. PMID: 3196873.
      Citations: 1     Fields:    Translation:HumansCells
    61. Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood. 1988 Nov; 72(5):1784-9. PMID: 3052630.
      Citations: 14     Fields:    Translation:Humans
    62. Zander AR, Keating M, Dicke K, Dixon D, Pierce S, Jagannath S, Peters L, Horwitz L, Cockerill K, Spitzer G, et al. A comparison of marrow transplantation with chemotherapy for adults with acute leukemia of poor prognosis in first complete remission. J Clin Oncol. 1988 Oct; 6(10):1548-57. PMID: 3049949.
      Citations: 6     Fields:    Translation:Humans
    63. Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988 Aug 15; 62(4):672-6. PMID: 3165046.
      Citations: 5     Fields:    Translation:Humans
    64. Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer. 1988 Aug 15; 62(4):677-82. PMID: 3165047.
      Citations: 9     Fields:    Translation:Humans
    65. Vadhan-Raj S, Kellagher MJ, Keating M, Walters R, Gutterman JU. Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with bone marrow failure and malignancy. Behring Inst Mitt. 1988 Aug; (83):119-24. PMID: 2467646.
      Citations:    Fields:    Translation:HumansCells
    66. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 1988 Jul; 2(7):403-12. PMID: 3164797.
      Citations: 11     Fields:    Translation:Humans
    67. Vadhan-Raj S, Buescher S, LeMaistre A, Keating M, Walters R, Ventura C, Hittelman W, Broxmeyer HE, Gutterman JU. Stimulation of hematopoiesis in patients with bone marrow failure and in patients with malignancy by recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1988 Jul; 72(1):134-41. PMID: 3291976.
      Citations: 13     Fields:    Translation:HumansCells
    68. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988 Apr 01; 61(7):1441-6. PMID: 3162181.
      Citations: 43     Fields:    Translation:Humans
    69. Amato R, Kantarjian H, Walters R, Keating M. Rebound peripheral blastosis with subsequent remission during remission induction in a patient with acute promyelocytic leukemia. Cancer. 1988 Feb 15; 61(4):650-3. PMID: 3422175.
      Citations:    Fields:    Translation:HumansCells
    70. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol. 1988 Feb; 6(2):232-8. PMID: 3276823.
      Citations: 19     Fields:    Translation:Humans
    71. Heinemann V, Murray D, Walters R, Meyn RE, Plunkett W. Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. Cancer Chemother Pharmacol. 1988; 22(3):205-10. PMID: 3165725.
      Citations: 7     Fields:    Translation:Humans
    72. Childs CC, Hirsch-Ginsberg C, Culbert SJ, Ahearn M, Reuben J, Trujillo JM, Cork A, Walters RR, Freireich EJ, Stass SA. Lineage heterogeneity in acute leukemia with the t(4;11) abnormality: implications for acute mixed lineage leukemia. Hematol Pathol. 1988; 2(3):145-57. PMID: 3220802.
      Citations: 1     Fields:    Translation:HumansCells
    73. Lee J, Talpaz M, Walters R, Gutterman JU, Blick M. Aberrant expression of the K-ras proto-oncogene in B-cell malignancies. Hematol Pathol. 1988; 2(4):229-37. PMID: 3075608.
      Citations:    Fields:    Translation:HumansCells
    74. Walters RS, Kantarjian HM, Keating MJ, Talpaz M, Childs CC, McCredie KB, Freireich EJ. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron. Cancer. 1987 Oct 15; 60(8):1708-12. PMID: 3477315.
      Citations: 3     Fields:    Translation:Humans
    75. Kantarjian H, Walters R. Implications of cytogenetic findings in secondary leukemia. Am J Clin Oncol. 1987 Oct; 10(5):453-6. PMID: 3477944.
      Citations:    Fields:    Translation:HumansCells
    76. Kantarjian HM, Keating MJ, McCredie KB, Walters R, Talpaz M, Smith TL, Freireich EJ. Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia. South Med J. 1987 Oct; 80(10):1228-32. PMID: 3477869.
      Citations: 5     Fields:    Translation:Humans
    77. Kurzrock R, Talpaz M, Kantarjian H, Walters R, Saks S, Trujillo JM, Gutterman JU. Therapy of chronic myelogenous leukemia with recombinant interferon-gamma. Blood. 1987 Oct; 70(4):943-7. PMID: 3115339.
      Citations: 14     Fields:    Translation:Humans
    78. Kurzrock R, Shtalrid M, Gutterman JU, Koller CA, Walters R, Trujillo JM, Talpaz M. Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia. Br J Haematol. 1987 Sep; 67(1):55-9. PMID: 3478080.
      Citations: 3     Fields:    Translation:HumansCells
    79. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987 Sep; 83(3):445-54. PMID: 3477958.
      Citations: 43     Fields:    Translation:HumansCells
    80. Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ. Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer. 1987 Jul 15; 60(2):149-55. PMID: 3474052.
      Citations: 6     Fields:    Translation:Humans
    81. Kurzrock R, Kloetzer WS, Talpaz M, Blick M, Walters R, Arlinghaus RB, Gutterman JU. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood. 1987 Jul; 70(1):233-6. PMID: 2885048.
      Citations: 8     Fields:    Translation:HumansCells
    82. Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. J Clin Oncol. 1987 May; 5(5):710-21. PMID: 3553435.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    83. Kantarjian HM, Keating MJ, Walters RS, Smith TL, McCredie KB, Freireich EJ. Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer. 1987 Apr 01; 59(7):1258-63. PMID: 3469011.
      Citations: 4     Fields:    Translation:Humans
    84. Dicke KA, Jagannath S, Walters RS, Horwitz LJ, Spitzer G. The role of autologous bone marrow transplantation in acute leukemia. Ann N Y Acad Sci. 1987; 511:468-72. PMID: 3326476.
      Citations:    Fields:    Translation:Humans
    85. Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ. Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res. 1987; 11(2):119-33. PMID: 3469482.
      Citations: 8     Fields:    Translation:Humans
    86. Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T, McCredie KB, Freireich EJ. Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol. 1987; 78 Suppl 1:120-6. PMID: 3124434.
      Citations: 2     Fields:    Translation:Humans
    87. Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986 Dec; 4(12):1748-57. PMID: 3783201.
      Citations: 44     Fields:    Translation:Humans
    88. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Smith TL, Talpaz M, Beran M, Cork A, Trujillo JM, Freireich EJ. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer. 1986 Nov 01; 58(9):2023-30. PMID: 3463397.
      Citations: 5     Fields:    Translation:HumansCells
    89. Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Bodey GP, Freireich EJ. Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia. Cancer. 1986 Oct 15; 58(8):1603-8. PMID: 3463390.
      Citations:    Fields:    Translation:Humans
    90. Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med. 1986 Sep; 81(3):387-94. PMID: 3463209.
      Citations: 20     Fields:    Translation:Humans
    91. Kantarjian HM, Keating MJ, Walters RS, Beran M, McLaughlin P, McCredie KB, Freireich EJ. The association of specific "favorable" cytogenetic abnormalities with secondary leukemia. Cancer. 1986 Aug 15; 58(4):924-7. PMID: 3719557.
      Citations: 3     Fields:    Translation:Humans
    92. Jones PG, Rolston KV, Fainstein V, Elting L, Walters RS, Bodey GP. Aztreonam therapy in neutropenic patients with cancer. Am J Med. 1986 Aug; 81(2):243-8. PMID: 3526885.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    93. Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT, Cork A, Trujillo JM, Freireich EJ. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med. 1986 May; 80(5):789-97. PMID: 3458366.
      Citations: 24     Fields:    Translation:Humans
    94. Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985 Dec; 66(6):1326-35. PMID: 3864497.
      Citations: 24     Fields:    Translation:HumansCells
    95. Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun; 12(2 Suppl 3):98-104. PMID: 3859935.
      Citations: 1     Fields:    Translation:Humans
    96. Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Dalton WT, Hittleman W, Freireich EJ. A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia. J Clin Oncol. 1985 Jun; 3(6):793-8. PMID: 3859586.
      Citations: 1     Fields:    Translation:Humans
    97. Estey EH, Keating MJ, Smith TL, McCredie KB, Legha SS, Walters RS, Bodey GP, Freireich EJ. Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. J Clin Oncol. 1984 Feb; 2(2):102-6. PMID: 6583328.
      Citations: 1     Fields:    Translation:Humans
    98. Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU. Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med. 1983 Dec; 99(6):789-92. PMID: 6580836.
      Citations: 11     Fields:    Translation:Humans
    99. Phase I-II study of aziridinylbenzoquinone in acute leukemia.
    100. Assessing compliance with established Pneumonia Core Measures at a comprehensive cancer center. Journal for healthcare quality : official publication of the National Association for Healthcare Quality. 37:232-244.
    101. 60 Years of survival outcomes at the university of Texas MD Anderson cancer center.
    102. Value-Based Breast Cancer Care. Annals of Surgical Oncology. 1-6.
    WALTERS's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (342)
    Explore
    _
    Co-Authors (46)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _